S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80
S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80
S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80
S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80

Puma Biotechnology Stock Forecast, Price & News

+0.07 (+2.52%)
(As of 06/29/2022 05:49 PM ET)
Today's Range
50-Day Range
52-Week Range
383,096 shs
Average Volume
522,215 shs
Market Capitalization
$128.17 million
P/E Ratio
Dividend Yield
Price Target
30 days | 90 days | 365 days | Advanced Chart

Receive PBYI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Puma Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

PBYI Stock Forecast (MarketRank)

Overall MarketRank

2.52 out of 5 stars

Medical Sector

121st out of 1,432 stocks

Pharmaceutical Preparations Industry

44th out of 685 stocks

Analyst Opinion: 3.0Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 1.9 5 -4 -3 -2 -1 -
Puma Biotechnology logo

About Puma Biotechnology (NASDAQ:PBYI)

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

PBYI Stock News Headlines

Puma Biotechnology Q1 2022 Earnings Preview
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
3 Analysts


Net Income
$-29.13 million
Pretax Margin


Sales & Book Value

Annual Sales
$253.20 million
Book Value
($0.06) per share


Free Float
Market Cap
$128.17 million

Puma Biotechnology Frequently Asked Questions

Should I buy or sell Puma Biotechnology stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Puma Biotechnology in the last year. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" Puma Biotechnology stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PBYI, but not buy additional shares or sell existing shares.
View analyst ratings for Puma Biotechnology
or view top-rated stocks.

What is Puma Biotechnology's stock price forecast for 2022?

3 analysts have issued 12-month target prices for Puma Biotechnology's stock. Their PBYI stock forecasts range from $6.00 to $12.00. On average, they anticipate Puma Biotechnology's share price to reach $9.25 in the next twelve months. This suggests a possible upside of 224.6% from the stock's current price.
View analysts' price targets for Puma Biotechnology
or view top-rated stocks among Wall Street analysts.

How has Puma Biotechnology's stock performed in 2022?

Puma Biotechnology's stock was trading at $3.04 on January 1st, 2022. Since then, PBYI stock has decreased by 6.3% and is now trading at $2.85.
View the best growth stocks for 2022 here

When is Puma Biotechnology's next earnings date?

Puma Biotechnology is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Puma Biotechnology

How were Puma Biotechnology's earnings last quarter?

Puma Biotechnology, Inc. (NASDAQ:PBYI) posted its quarterly earnings data on Thursday, May, 5th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.05. The biopharmaceutical company had revenue of $45.70 million for the quarter, compared to the consensus estimate of $45.07 million. Puma Biotechnology had a negative trailing twelve-month return on equity of 843.16% and a negative net margin of 24.42%. The firm's quarterly revenue was down 53.5% on a year-over-year basis. During the same period last year, the company earned $0.40 earnings per share.
View Puma Biotechnology's earnings history

Who are Puma Biotechnology's key executives?

Puma Biotechnology's management team includes the following people:
  • Mr. Alan H. Auerbach, Founder, Chairman, Pres, CEO & Sec. (Age 52, Pay $1.11M) (LinkedIn Profile)
  • Mr. Maximo F. Nougues, CFO & Principal Accounting Officer (Age 53, Pay $627.85k) (LinkedIn Profile)
  • Dr. Alvin F. Wong Pharm.d., Chief Scientific Officer
  • Mr. Douglas Hunt B.Sc., FRAPS, Sr. VP of Regulatory Affairs, Medical Writing & Project Management (Age 57, Pay $509.04k)
  • Mr. Jeffrey Jerome Ludwig, Chief Commercial Officer (Age 56, Pay $735.01k)
  • Mr. Mariann Ohanesian, Sr. Director of Investor Relations

What other stocks do shareholders of Puma Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Puma Biotechnology investors own include (MDVN) (MDVN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), Dynavax Technologies (DVAX), United Airlines (UAL), (KITE) (KITE), Array Technologies (ARRY), Freeport-McMoRan (FCX) and (CELG).

What is Puma Biotechnology's stock symbol?

Puma Biotechnology trades on the NASDAQ under the ticker symbol "PBYI."

How do I buy shares of Puma Biotechnology?

Shares of PBYI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Puma Biotechnology's stock price today?

One share of PBYI stock can currently be purchased for approximately $2.85.

How much money does Puma Biotechnology make?

Puma Biotechnology (NASDAQ:PBYI) has a market capitalization of $128.17 million and generates $253.20 million in revenue each year. The biopharmaceutical company earns $-29.13 million in net income (profit) each year or ($1.200010) on an earnings per share basis.

How many employees does Puma Biotechnology have?

Puma Biotechnology employs 196 workers across the globe.

How can I contact Puma Biotechnology?

Puma Biotechnology's mailing address is 10880 WILSHIRE BOULEVARD SUITE 2150, LOS ANGELES CA, 90024. The official website for Puma Biotechnology is www.pumabiotechnology.com. The biopharmaceutical company can be reached via phone at (424) 248-6500, via email at [email protected], or via fax at 424-248-6501.

This page (NASDAQ:PBYI) was last updated on 6/30/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.